Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Urticaria Review & Update
Description
The presentation provides a comprehensive review and update on urticaria, emphasizing its complexity, types, and treatment options. Chronic urticaria is predominantly seen in females and is often misdiagnosed due to its transient nature. The speaker highlights the importance of understanding the disease's pathology, particularly the role of mast cells in urticaria's manifestation. Two main categories are discussed: acute and chronic urticaria, with the latter often being idiopathic. Specialized treatments, like omalizumab and dupilumab, have emerged, both targeting the autoimmune pathways involved in urticaria. Omalizumab has shown a high response rate, making it a cornerstone therapy, while dupilumab shows promise in trials, targeting IL-4 and IL-13 pathways. Additionally, remybrutinib, a BTK inhibitor, offers a novel route for treatment, affecting the intracellular mechanisms of mast cell activation. The speaker argues for dermatologists to take a leading role in managing urticaria, supported by advancements in treatment options and complexity of the condition. The focus is on empowering dermatologists to address this skin condition more effectively, utilizing emerging therapies that simplify management for patients.
View moreConclusions
- Urticaria is a heterogeneous, inflammatory skin condition that predominantly affects females.
- Most patients with urticaria experience chronic disease rather than acute episodes.
- Mast cell activation and degranulation are central to the pathogenesis of urticaria, influencing the development of its symptoms.
- Chronic spontaneous urticaria (CSU) is often associated with various coexisting autoimmune conditions, particularly thyroid autoimmunity.
- The vast majority of patients with CSU remain chronically affected, with significant percentages failing to achieve remission even after years.
- Antihistamine therapy is insufficient for about 50% of CSU patients, necessitating alternative treatment options.
- Omalizumab is highly effective, showing a complete response rate of approximately 76% in patients with CSU.
- Dupilumab has shown promising results in reducing symptoms of CSU, with a significant reduction in itch and hives, but its efficacy in patients previously treated with omalizumab is uncertain.
- New treatments targeting different pathways, including BTK inhibitors and IL-4/IL-13 inhibitors, are in development and show potential for managing CSU.
- Dermatologists should take a more active role in the management of CSU instead of referring patients to allergists.
- Kozel, 2001
- Beltrani, 2002
- Van Der Valk, 2002
- Kulthanan, 2007
- Boonpiyathad, 2016
- Chuamanochan, 2016
- Kim, 2018
- Varricchi et al. (2017) Front. Immunol.
- Maurer et al. (2020) Int Arch Allergy Immunol.
- Ghazanfar MN et al. (2020) World Allergy Organ J.
- Altrichter et al. (2021) Allergy Asthma Immunol Res.
- Giustizieri et al. (2004) JACI.
- Tharp, M. D. et al. (2019) JAMA Derm.
- Maurer M et al. (2022) JACI; Novartis Nov. 9, 2023 Press Release.